Food supplements Public health

Ineldea innovates to fight sarcopenia with Sarcofontil

sarcopénie sarcopenia Sarconfontil Ineldea
Laura
Written by Laura

Read this article in Français

With an increasingly visible aging population and a baby boomer generation (49-70 years old), age-related issues are more than a trend: there is a real need. This generation is the main target of the nutrition business for 72% of manufacturers. In response to this need, Ineldea is tackling the sarcopenia market with its new food supplement Sarcofontil.

Sarcopenia is an age-related syndrome that manifests itself as muscle loss and therefore a loss of physical strength as people age. Sarcopenia is a major public health problem, with a european prevalence of 11% in 2016, tending to reach almost 13% in 2045.

sarcopenie Sarconfontil Ineldea responds to this problem with a judicious combination of:

  • Leucine, an essential amino acid for muscles
  • Vitamin B6, involved in the normal metabolism of proteins
  • Vitamin D, involved in normal muscle function
  • HMB (hydroxy-methylbutyrate), which reduces muscle protein breakdown and optimizes leucine metabolism

Ineldea is launching here in an uncompetitive environment. Indeed, food supplements targeting sarcopenia are poorly represented. We can still mention Myo-Cit® from the Citrage laboratory, launched in 2011. However, competition may be found elsewhere, with NOC-type products or fortified food products.

print

About the author

Laura

Laura

Consultante-Chef de Projet chez Nutrikéo.
Mes domaines de prédilection : nutraceutique, marketing agroalimentaire, alimentation durable, innovations en alimentation...

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Share This